0001104659-26-061166
SEC filingQ1 operating loss widened 3.6% to $4.0M due to higher G&A expenses despite R&D efficiencies from lower vanoglipel development and employee costs, while cash burn from operations improved to $4.3M and EPS dilution moderated to -$0.79 amid share count expansion.
Net loss reached $3.8 million, or -$0.79 diluted EPS—a 4.1% increase from $3.7 million and -$0.36 EPS in Q1 FY2025. The less severe per-share impact stems from a higher weighted average share count following equity issuances, including fixed-price Series C and D Common Warrants without variable features. These dynamics highlight our reliance on capital markets to support operations amid dilutive financing.
Cash flow from operations consumed $4.3 million, an improvement from $4.8 million prior year, driven by the moderated net loss and working capital efficiencies. No material changes occurred in key operating information, underscoring steady execution despite losses. Our liquidity position funds R&D priorities, but management notes expectation of sustained net losses and negative cash flows due to ongoing clinical trials.
The unaudited statements assume going concern continuity without adjustments for potential uncertainties. Investors should note our focus on vanoglipel Phase 2a progress, where cost discipline in direct development and personnel supports trial advancement, even as overall expenses pressure operating results. This positions us to deliver on pipeline milestones while managing burn rate improvements.